{"nctId":"NCT00465816","briefTitle":"Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612","startDateStruct":{"date":"2007-04-11"},"conditions":["Infections, Meningococcal"],"count":611,"armGroups":[{"label":"Nimenrix + Twinrix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Nimenrix (Meningococcal vaccine 134612)","Biological: Twinrix"]},{"label":"Nimenrix Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Nimenrix (Meningococcal vaccine 134612)"]},{"label":"Twinrix Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Twinrix"]}],"interventions":[{"name":"Nimenrix (Meningococcal vaccine 134612)","otherNames":[]},{"name":"Twinrix","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol\n* A male or female between, and including, 11 and 17 years of age at the time of the first dose of vaccine.\n* Written informed consent obtained from the subject/ from the parent or guardian of the subject.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n* Previously completed routine childhood vaccinations to the best of his/her/the parents'/guardians' knowledge.\n* If the subject is female and of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine.\n* Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C, W-135 and/or Y within the last five years.\n* Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroup A, C, W-135 and/or Y.\n* Previous vaccination with tetanus toxoid within the last month.\n* Previous vaccination with hepatitis A and/or hepatitis B vaccine.\n* Seropositivity for hepatitis A IgG, hepatitis B surface antigen, hepatitis B core antibody and/or hepatitis B surface antigen at screening.\n* History of hepatitis A, hepatitis B and/or Neisseria meningitidis infection.\n* Known exposure to hepatitis A and/or hepatitis B virus within three months preceding the first dose of study vaccine.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.\n* A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.\n* History of reactions or allergic disease likely to be exacerbated by any component of either vaccine.\n* Major congenital defects or serious chronic illness.\n* Acute disease at the time of enrolment.\n* Administration of immunoglobulins and/or any blood products within the three months preceding the dose of study vaccine or planned administration during the study period.\n* Pregnant or lactating female.\n* History of chronic alcohol consumption and/or drug abuse.\n* Female planning to become pregnant or planning to discontinue contraceptive precautions.","healthyVolunteers":true,"sex":"ALL","minimumAge":"11 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Meningococcal Polysaccharide A Serum Bactericidal Antibodies/Assay, Using Baby Rabbit Complement for Assay (rSBA-MenA), rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers","description":"The rSBA titers were expressed as geometric mean titers (GMTs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5263.9","spread":null},{"groupId":"OG001","value":"5211.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4344.6","spread":null},{"groupId":"OG001","value":"4926.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8922.1","spread":null},{"groupId":"OG001","value":"8987.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9291.5","spread":null},{"groupId":"OG001","value":"9492.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Seroconverted for Hepatitis A","description":"A seroconverted subject was defined as a subject with anti-Hepatitis A virus (HAV) antibody concentration greater than or equal to 15 milli-International Units per Milliliter (mIU/mL) in previously seronegative subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"321","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Seroprotected for Hepatitis B","description":"A seroprotected subject was defined as a subject with anti-Hepatitis B surface antigen (HBs) antibody concentration greater than or equal to 10 milli-International Units per Milliliter (mIU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"327","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With a Vaccine Response to MenA, MenC, MenY and MenW-135","description":"Vaccine response is defined as an rSBA titer of at least 1:32 in subjects initially seronegative \\[rSBA titer below1:8\\] and as a 4-fold increase in titer in subjects initially seropositive \\[rSBA titre greater than or equal to 1:8\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"246","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"333","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"346","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"335","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers Above Predefined Cut-off Values","description":"The cut-off values assessed were greater than or equal to (≥) 1:8 and ≥ 1:128.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"352","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"359","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"277","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"360","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"275","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"359","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"352","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"358","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"359","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":null},{"groupId":"OG001","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"359","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PSA (Polysaccharide A), Anti-PSC (Polysaccharide C), Anti-PSW-135 (Polysaccharide W-135), and Anti-PSY (Polysaccharide Y) Antibody Concentrations","description":"Concentrations were provided as Geometric Mean Concentrations expressed as micrograms per milliliter (µg/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":null},{"groupId":"OG001","value":"0.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.23","spread":null},{"groupId":"OG001","value":"18.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":null},{"groupId":"OG001","value":"0.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.58","spread":null},{"groupId":"OG001","value":"21.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":null},{"groupId":"OG001","value":"0.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.78","spread":null},{"groupId":"OG001","value":"6.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":null},{"groupId":"OG001","value":"0.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.04","spread":null},{"groupId":"OG001","value":"12.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135, and Anti-PSY Antibody Concentrations Above Pre-defined Cut-off Values","description":"The cut-off values assessed include greater than or equal to (≥) 0.3 micrograms per milliliter (µg/mL) and ≥ 2.0 µg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"172","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-Tetanus Toxoid (TT) Antibody Concentrations","description":"Concentrations were provided as Geometric Mean Concentrations expressed as International Units per milliliter (IU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.800","spread":null},{"groupId":"OG001","value":"1.020","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.794","spread":null},{"groupId":"OG001","value":"17.252","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-tetanus Toxoid Antibody Concentrations Above the Pre-defines Cut-off Value","description":"The cut-off value assessed was greater than or equal to 0.1 International Units per milliliter (IU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"293","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"354","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]}]},{"type":"SECONDARY","title":"rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers at Month 7","description":"The rSBA titers were expressed as geometric mean titers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2121.6","spread":null},{"groupId":"OG001","value":"2298.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"952.4","spread":null},{"groupId":"OG001","value":"1053.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3283.4","spread":null},{"groupId":"OG001","value":"3497.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4432.7","spread":null},{"groupId":"OG001","value":"4455.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers Above Predefined Cut-off Values at Month 7","description":"The cut-off values assessed were greater than or equal to (≥) 1:8 and ≥ 1:128.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"330","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"332","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"334","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"333","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"329","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"318","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"333","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"332","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations at Month 7","description":"Concentrations were provided as Geometric Mean Concentrations expressed as micrograms per milliliter (µg/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.14","spread":null},{"groupId":"OG001","value":"3.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.28","spread":null},{"groupId":"OG001","value":"4.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.46","spread":null},{"groupId":"OG001","value":"3.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.76","spread":null},{"groupId":"OG001","value":"4.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations Above Pre-defined Cut-off Values at Month 7","description":"The cut-off values assessed include greater than or equal to (≥) 0.3 micrograms per milliliter (µg/mL) and ≥ 2.0 µg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunoglobulin G (IgG) Anti-HAV Antibody Concentrations","description":"Concentrations are given as Geomatric Mean Concentrations expressed as milli-Internatinal Units per Milliliter (mIU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5876.7","spread":null},{"groupId":"OG001","value":"6739.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With IgG Anti-HAV Antibody Concentrations Above the Pre-defined Cut-off Value","description":"The cut-off value assessed was greater than or equal to 15 milli-Internatinal Units per Milliliter (mIU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"331","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]}]},{"type":"SECONDARY","title":"IgG Anti-HBs Antibody Concentrations","description":"Concentrations are given as Geomatric Mean Concentrations expressed as milli-Internatinal Units per Milliliter (mIU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6088.2","spread":null},{"groupId":"OG001","value":"7654.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With IgG Anti-HB Antibody Concentrations Above the Pre-defined Cut-off Value","description":"The cut-off value assessed was greater than or equal to 10 milli-Internatinal Units per Milliliter (mIU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"327","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Solicited Local Symptoms Post-meningococcal Vaccination","description":"Solicited local symptoms assessed include pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Solicited Local Symptoms Post-Twinrix Vaccination","description":"Solicited local symptoms assessed include pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"228","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Solicited General Symptoms","description":"Solicited general symptoms assessed include fatigue, fever (axillary temperature greater than or equal to 37.5 degrees Celcius), gastrointestinal symptoms and headache. Any = occurrence of the symptom regardless of intensity grade. Dose 1 = post-Nimenrix and post-Twinrix for the Nimenrix + Twinrix Group, post-Twinrix for the Twinrix Group and post-Nimenrix for the Nimenrix Group, Dose 2, 3 and Across doses = post-Twinrix for the Nimenrix + Twinrix Group and for the Twinrix Group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG002","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG002","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)","description":"Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Specific AEs of New Onset of Chronic Illnesses","description":"Specific AEs of new onset of chronic illnesses include e.g. autoimmune disorders, asthma, type I diabetes and allergies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Rash","description":"Rashes include e.g. hives, idiopathic thrombocytopenic purpura, petechiae.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Conditions Prompting Emergency Room Visits","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":367},"commonTop":["Pain at the injection site","Pain at the injection site","Fatigue","Headache","Gastrointestinal symptoms"]}}}